SCHEMBL13469124

SCHEMBL13469124

CCc1cccc(NC(=O)C(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
TP53 P04637 1/20 0.59
SMN1; SMN2 Q16637 6/20 0.58
LMNA P02545 1/20 0.58
HDAC3 O15379 2/20 0.56
HDAC4 P56524 2/20 0.56
HDAC1 Q13547 2/20 0.56
HDAC7 Q8WUI4 2/20 0.56
HDAC2 Q92769 2/20 0.56
HDAC10 Q969S8 2/20 0.56
HDAC11 Q96DB2 2/20 0.56
HDAC8 Q9BY41 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
HDAC9 Q9UKV0 2/20 0.56
HDAC5 Q9UQL6 2/20 0.56
HPGD P15428 1/20 0.56
MAPK1 P28482 1/20 0.56
ALDH1A1 P00352 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MEN1 O00255 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13255715 0.86 MAPT (0.59) MAPTTP53SMN1; SMN2LMNAHDAC3
SCHEMBL4611142 0.85 SMN1; SMN2 (0.56) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL6110283 0.85 SMN1; SMN2 (0.56) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL25144628 0.84 SMN1; SMN2 (0.55) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL2474191 0.83 SMN1; SMN2 (0.54) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL26785129 0.83 SMN1; SMN2 (0.61) MAPTTP53SMN1; SMN2LMNAMAPK1
SCHEMBL11272351 0.83 MAPT (0.55) MAPTTP53SMN1; SMN2LMNAHDAC3
SCHEMBL8996654 0.82 MAPT (0.64) MAPTTP53SMN1; SMN2LMNAHDAC3
SCHEMBL4319038 0.82 MAPT (0.64) MAPTTP53SMN1; SMN2LMNAHDAC3
SCHEMBL9979313 0.81 MAPT (0.59) MAPTTP53SMN1; SMN2LMNAHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-27 US disclosed
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2020-04-16 US disclosed
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2020-02-25 US disclosed
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF PHARMAKEA, INC. 2019-06-27 US disclosed
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2019-04-25 US disclosed
US-10206931-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-19 US disclosed
US-20170369443-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2017-12-28 US disclosed
WO-2012139891-A1 SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS BAYER CROPSCIENCE AG (DE) 2012-10-18 WO disclosed
CN-1140500-C Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives ��˹��ŵ�� 2004-03-03 CN disclosed
CN-1268112-A Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives thereof NOVARTIS AG (CH) 2000-09-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators PDE4A, PDE4B, PDE5A MAPT 4661/4885TP53 3139/4885SMN1; SMN2 3416/4885
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX MAPT 3903/4885TP53 4347/4885SMN1; SMN2 2346/4885
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX MAPT 3903/4885TP53 4347/4885SMN1; SMN2 2346/4885
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX MAPT 3903/4885TP53 4347/4885SMN1; SMN2 2346/4885
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX MAPT 3903/4885TP53 4347/4885SMN1; SMN2 2346/4885
US-20170369443-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX MAPT 3903/4885TP53 4347/4885SMN1; SMN2 2346/4885
US-10206931-B2 Therapeutic compounds and uses thereof EP300, CREBBP, HDAC1 MAPT 2745/4885TP53 2086/4885SMN1; SMN2 1409/4885
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF LOXL2, LOXL1, LOXL3 MAPT 4698/4885TP53 2460/4885SMN1; SMN2 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.